Mayo Clinic Pharmacy Grand Rounds

Natalie T. Hagy, PharmD describes the monoamine and glutaminergic pathway for the treatment of major depressive disorder, recognizes response and remission rates of first line treatment for major depressive disorder and describes the clinical trials for dextromethorphan-bupropion and its impact on the landscape of major depressive disorder. For more pharmacy content, follow Mayo Clinic Pharmacy Re...

Lauren R. Stonerock, PharmD ( @LStonerockRx ) reviews the history of insulin delivery technology and its impact on diabetes management, identifies patient-specific factors associated with successful insulin pump use and discusses current insulin pumps and highlight their specific features. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host, Garrett...

Chelsea M. Morken, PharmD ( @ChelseaMorken ) explains the pathophysiology of rheumatoid arthritis (RA), describes the literature regarding cardiovascular risks with Janus-kinase inhibitors and recognizes appropriate initial therapy based on patient specific factors. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host, Garrett E. Schramm, Pharm. D., ...

Uzoamaka (Uzo) C. Abajue, PharmD ( @Uzo_Chi ) discusses the manifestations, diagnosis, and classification of chemotherapy induced cardiotoxicity, identifies causative oncologic agents responsible for cardiotoxicities and outlines strategies for cardiotoxicity management due to oncologic agents. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host, Ga...

Megan A. Galle, PharmD ( @meganciclovir ) reviews eculizumab’s mechanism of action and its role in treating antibody mediated rejection following solid organ transplantation, discusses laboratory testing methods available for eculizumab therapeutic drug monitoring and describes the role of therapeutic drug monitoring in eculizumab treatment optimization. For more pharmacy content, follow Mayo Clin...

Devon S. Stonerock, PharmD ( @DevonStoneRx ) describes the underlying pathophysiology driving the development and progression of aplastic anemia, outlines treatment options based on patient specific factors and recognizes key toxicities, drug interactions, and administration considerations for patients receiving immunosuppressive therapy. For more pharmacy content, follow Mayo Clinic Pharmacy Resi...

Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections . For more pharmacy content, fo...

Kyle A. Hess, PharmD ( @KyleHessPHarmD ) describes the rationale for early use of vasopressors with multiple mechanisms of action in patients with septic shock, reviews the literature examining the early initiation of vasopressin in patients with septic shock and identifies patient characteristics associated with positive response to angiotensin II. For more pharmacy content, follow Mayo Clinic Ph...

Divya A. Khandekar, PharmD, MS ( @pharmdiv ) discusses the basic principles of radiation therapy in the treatment of cancer, describes the etiology and pathophysiology of toxicities caused by radiation therapy and identifies which pharmacological treatments for radiation toxicity management are evidence-based. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes...

Nikitha Yagnala, PharmD ( @nikithayagnala ) recognizes the physiologic consequences of sleep disturbances in critically ill patients, discusses the mechanisms of sleep promotion for pharmacologic sleep agents and outlines appropriate utilization of pharmacologic sleep agents in critically ill patients. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the...

Andrew J. Jatis, PharmD (Twittter: @jatis_rx ) Identifies adverse consequences of fluid overload in critically ill patients, summarizes literature assessing the efficacy and safety of fluid stewardship strategies and generates patient-specific plans for fluid management based on available evidence. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host...

Jo Ann Leal, PharmD (Twitter: @jojopharmd ) describes the implications of various CYP2C19 phenotypes on clopidogrel metabolism and activity, analyzes the available literature evaluating outcomes of clopidogrel versus ticagrelor in ischemic stroke patients based on CYP2C19 metabolizer status and selects a preferred antiplatelet agent and dose for secondary prevention of ischemic stroke given patien...

KaShena L. Kennedy, PharmD (Twitter: @KaShenaKennedy ) reviews and identifies the pathophysiology, clinical manifestations, and diagnostic criteria for TA-TMA in pediatric patients, differentiates risk factors associated with TA-TMA and discusses prophylactic treatment in pediatric patients and explores treatment and emerging therapy options of TA-TMA in pediatric patients. For more pharmacy conte...

Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx ) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs...

Kyle A. Hess, PharmD (Twitter: @KyleHessPharmD ) describes current guideline recommendations for duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention, compares and contrasts strategies for antiplatelet regimens for reduced duration DAPT and selects an appropriate duration of therapy when utilizing shortened DAPT. For more pharmacy content, follow Mayo Clinic Ph...

Nikitha Yagnala, PharmD (Twitter: @NikithaYagnala ) describes laboratory tests used to estimate DOAC plasma levels, reviews current literature exploring the association between DOAC plasma levels and clinical outcomes and outlines appropriate utilization and interpretation of DOAC plasma levels in clinical practice. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPha...

Divya A. Khandekar, PharmD, MS (Twitter: @pharmdiv ) describes the etiology of febrile neutropenia in patients with hematological malignancies, summarizes guideline-based recommendations for antibiotic discontinuation in patients with febrile neutropenia and discusses primary literature supporting early antibiotic discontinuation in patients with febrile neutropenia. For more pharmacy content, fol...

Andrew J. Jatis, PharmD ( Twitter: @jatis_rx ) reviews the pharmacology and drug characteristics of dalbavancin and oritavancin, describes current literature assessing the safety and efficacy of FDA approved and off-label indications for lipoglycopeptide use in clinical practice and discusses pharmacoeconomic implications of lipoglycopeptide use in clinical practice. For more pharmacy content, fol...

Kaylee A. Clark, PharmD describes the basic principles of maintenance therapies after allogeneic HSCT, discusses evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute lymphoblastic leukemia and reviews evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute myeloid leukemia. For more pharmacy content, follow Mayo C...

Kyle J. Eickman, PharmD, describe the goals of six sigma methodology and review examples of its application within pharmacy dispensing, reviews DMAIC methodology and describes how lean and six sigma can be used to achieve the same goals of patient safety.  For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host, Garrett E. Schramm, Pharm. D.,  @garrett_...

Dimple R. Dhakal, PharmD describes the pharmacodynamics and pharmacokinetics of methadone, identifies and discusses clinical practice guidelines for the safe use of methadone and evaluates evidence for CYP2B6-guided methadone use. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes  or the host, Garrett E. Schramm, Pharm. D.,  @garrett_schramm  on Twitter! You c...

Julie L. Cunningham, PharmD, BCPP; M. Zeeshan Rizwan, PharmD, BCPS, BCCCP; Christi A. Jen, PharmD, BCPS, FASHP, FAzPA; and Kristina L. Wescott, PharmD, BCPS identify appropriate non-stigmatizing language related to opioids and addiction in the context of patient care discussions, discuss risks for opioid harms related to individual risks at points of transitions of patient care, review interventio...

Hannah M. Brokmeier, PharmD, describes the pathophysiology behind the pharmacologic targets in ACLS, discusses the role of vasopressin, steroids, and epinephrine in cardiac arrest management, and explains the mechanism and evidence behind administering adjunct agents during ACLS. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs  @MayoPharmRes  or the host, Garrett E. Schra...

Lauren M. Dolly, PharmD, recalls the etiology and pathophysiology of TRD, discusses the role of pharmacogenomics in L-methylfolate for TRD, selects a preferred agent for a patient with TRD with evidence to support its use. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs  @MayoPharmRes  or the host, Garrett E. Schramm, Pharm. D.,  @garrett_schramm  on Twitter! You can also...

Pooja Ojha, PharmD, describes what bias in artificial intelligence entails, discusses implications of bias in artificial intelligence, evaluates mitigation strategies for bias in artificial intelligence. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs  @MayoPharmRes  or the host, Garrett E. Schramm, Pharm. D.,  @garrett_schramm  on Twitter! You can also connect with the M...